StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) to a sell rating in a research note issued to investors on Friday.
Several other analysts have also commented on EYPT. Chardan Capital reaffirmed a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Citigroup began coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 price target on the stock. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.
Check Out Our Latest Research Report on EYPT
EyePoint Pharmaceuticals Stock Down 4.5 %
EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The company had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Equities analysts expect that EyePoint Pharmaceuticals will post -2.13 EPS for the current year.
Hedge Funds Weigh In On EyePoint Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its position in shares of EyePoint Pharmaceuticals by 4.4% in the fourth quarter. Legal & General Group Plc now owns 46,263 shares of the company’s stock valued at $345,000 after acquiring an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of EyePoint Pharmaceuticals by 39.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after acquiring an additional 1,940 shares in the last quarter. Invesco Ltd. lifted its position in shares of EyePoint Pharmaceuticals by 16.1% in the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company’s stock valued at $117,000 after acquiring an additional 2,177 shares in the last quarter. Teacher Retirement System of Texas lifted its position in shares of EyePoint Pharmaceuticals by 22.4% in the fourth quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company’s stock valued at $113,000 after acquiring an additional 2,782 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of EyePoint Pharmaceuticals by 3.5% in the fourth quarter. Swiss National Bank now owns 100,000 shares of the company’s stock valued at $745,000 after acquiring an additional 3,400 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.
EyePoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
See Also
- Five stocks we like better than EyePoint Pharmaceuticals
- How to Evaluate a Stock Before Buying
- How to Build the Ultimate Everything ETF Portfolio
- Golden Cross Stocks: Pattern, Examples and Charts
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Do ETFs Pay Dividends? What You Need to Know
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.